Appili Therapeutics
@Appili
Followers
455
Following
100
Media
68
Statuses
381
Dedicated to identifying, acquiring and advancing novel therapeutics for #InfectiousDisease $APLI $APLIF
Canada
Joined August 2015
In 2025, Appili submitted multiple U.S. funding proposals representing up to US$90M. If awarded, the funds would support critical development activities across the portfolio. Awards from proposals are anticipated to be announced in Q1 2026. $APLI $APLIF https://t.co/naPbHK3Ppp
0
0
0
Millions suffer from NTDs with limited treatment options. The FDA PRV program incentivizes biotechs to develop treatments for underserved populations. PRVs are transferable and highly valuable, with recent sales often exceeding $100 million! $APLI $APLIF https://t.co/ULgtfdwmZj
appilitherapeutics.com
PIPELINE Overview Diversified Pipeline Driving Near- And Long-Term Value Through Appili’s unique approach to drug development, we have created a pipeline containing a deliberate mix of market and...
0
0
0
@Appili reports financial and operational results for Q2 FY2026 - New @NIH NIAID funding award of up to US $40M - Multiple government proposals submitted, totalling up to US $90M $APLI $APLIF https://t.co/kXDZRnMI7W
appilitherapeutics.com
New NIAID Non-Dilutive Funding Award of up to US $40Million with US$90 Million in Pending Proposals Across Multiple Infectious Disease Programs LIKMEZ® (ATI-1501): Building Commercial Momentum in the...
0
0
0
CEO, Don Cilla will represent Appili at the 2025 @BARDA Innovation Symposium on Nov 20 in DC! Excited to connect with leaders, share our advances, and build partnerships advancing medical countermeasures. https://t.co/dRjlSxeLiE $APLI $APLIF #BARDAInnovation #Biotech
0
0
0
A new WHO report reveals over a billion people are affected by NTDs. ATI-1801 represents our commitment to addressing cutaneous leishmaniasis and bridging treatment gaps. Join us, governments & NGOs in prioritizing solutions for communities. $APLI $APLIF https://t.co/ZGesVyRBs0
who.int
The World Health Organization (WHO) today released the Global report on neglected tropical diseases 2025, the third in a series monitoring progress towards the 2030 targets set in the Road map for...
0
0
0
Appili will attend BARDA Innovation Symposium on November 20 in Washington, DC, highlighting our role as a trusted U.S. government partner. This event convenes a network of government agencies, non dilutive funders, investors and partners. $APLI $APLIF https://t.co/E5I2zGs1I1
0
0
0
ICYMI: Appili & Vitalex secured a US $40M NIAID contract to advance VXV-01, a first-in-class fungal vaccine. With no approved fungal vaccines for humans, VXV-01 aims to fill an urgent unmet need! #Biotech #Innovation #Appili $APLI $APLIF
0
0
0
Appili has secured a new NIAID contract worth up to US $40M — bringing our total government funding awards to US $74M, with US $97M more in pending applications. $APLI $APLIF #biotech #funding #innovation #Appili
https://t.co/ZLewq8cagy
0
0
0
Appili announces US$40M NIAID funding award to advance fungal vaccine, VXV-01, in collaboration with @VitalexBioscien. VXV-01 is designed to address the urgent threat of invasive fungal infections, affecting millions of people each year. $APLI $APLIF https://t.co/ZLewq8cagy
appilitherapeutics.com
Awarded contract base period of US$3.6 million to fund vaccine manufacturing with additional option periods to advance development through Phase 1 trials Submitted up to US$97 million in additional...
0
2
2
#Appili is pleased to report that all matters from our AGSM have been approved. These approvals enable us to execute key strategies and advance our pipeline of infectious disease solutions. Stay in touch: info@appilitherapeutics.com $APLI $APLIF https://t.co/hg8TyJvMRN
appilitherapeutics.com
HALIFAX, Nova Scotia - September 23, 2025 - Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious...
0
0
0
Appili submitted seven U.S. government funding proposals totaling US$137M. MCDC membership provides direct access to government stakeholders, industry partners, and DOD-aligned opportunities. $APLI $APLIF https://t.co/GJzmesK9bz
appilitherapeutics.com
Submitted two additional U.S. government funding proposals during the quarter, bringing the total proposals to US$137 million Accepted as a new member of U.S. Medical CBRN Defense Consortium,...
0
0
0
@Appili reports financial and operational results for Q1 FY2026. -Seven U.S. proposals submitted, totalling up to US $137M -US $3.3M PRMRP funding application to advance ATI-1701 to IND $APLI $APLIF https://t.co/GJzmesK9bz
appilitherapeutics.com
Submitted two additional U.S. government funding proposals during the quarter, bringing the total proposals to US$137 million Accepted as a new member of U.S. Medical CBRN Defense Consortium,...
0
0
0
Check out a new publication co-authored Dr. Gelhaus in Vaccine. The new manuscript showcases the preclinical efficacy of ATI‑1701, a novel live attenuated tularemia vaccine with strong potential as a biodefense countermeasure. https://t.co/GEDcNUl5Zj
#infectiousdiseases
appilitherapeutics.com
Peer-reviewed publication highlights ATI-1701’s robust protection against aerosolized Francisella tularensis exposure in multiple animal models HALIFAX, Nova Scotia, August 6, 2025 – Appili Therape...
0
0
0
Last week, Appili CDO, Dr. Nabors joined leaders from government and biodefense at CWMD&MCDC Membership Meeting. MCDC plays a critical role in fostering public–private partnerships to accelerate development of safe medical countermeasures. $APLI $APLIF https://t.co/stMqhlz0f9
appilitherapeutics.com
ABOUT US Overview ABOUT US Matching Novel Drug Development Programs With Clearly Defined Patient Needs in Infectious Disease Appili Therapeutics Inc., was founded in 2015 by a team of drug developm...
0
0
0
@Appili reports financial and operational results for FY2025 - Five U.S. government proposals submitted, totalling up to US$125M - LIKMEZ™ (ATI-1501) re-launched and commercial sales ongoing - FDA alignment on ATI-1801 development plans $APLI $APLIF https://t.co/ZISVK3uNvh
appilitherapeutics.com
LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing Five U.S. government proposals submitted, totalling up to US$125 million HALIFAX, Nova Scotia,...
0
0
0
Check out the latest publication from Dr. Gelhaus, Ph.D., and US researchers. “Together with the help of our colleagues, we can better understand host immune responses to tularemia, essential for advancing ATI-1701 towards the clinic" $APLI $APLIF https://t.co/bB3kiMrlBw
appilitherapeutics.com
A review of recent findings suggests that Appili’s biodefense vaccine, ATI-1701, may have a role in preventing tularemia outbreaks HALIFAX, Nova Scotia, May 1, 2025 – Appili Therapeutics Inc....
0
0
1
Appili has secured new U.S. & Mexican patents for LIKMEZ, boosting protection for our commercial stage asset until 2039! Now listed in the @US_FDA Orange Book. https://t.co/LUVZaNFddd $APLI $APLIF
appilitherapeutics.com
New patents provide additional composition of matter and methods of use claims, strengthening the protection for liquid oral taste-masked reformulation, LIKMEZ New subject matter listed in the U.S....
0
0
1
This week marks #WorldImmunizationWeek. #Appili is proud to support the World Immunization Week goal, for more children, adults and communities to be protected from vaccine-preventable diseases, allowing them to live happier, healthier lives $APLI $APLIF
It’s #WorldImmunizationWeek Vaccines have saved 154 million lives in the last 50 years. That’s 6 lives every minute. A reminder of what is #HumanlyPossible. Science saves lives. #VaccinesWork
https://t.co/gRxmdrRD54
0
0
0
“Collaboration across the globe is essential for tackling today’s urgent infectious disease challenges” At #WVC2025, Appili CDO Dr. Gary Nabors will join leaders across sectors to discuss innovative vaccine development, including ATI-1701. https://t.co/8VD4Gl8XWg $APLI $APLIF
0
0
0
ICYMI, Appili CEO, Don Cilla joined @Aditxt CEO, Amro Albanna at Friday's Weekly Update. The event highlighted the escalating threat of infectious diseases and emphasized the vital role partnerships play in addressing these challenges. $APLI $APLIF $ADTX https://t.co/sESBHB313E
0
0
0